Telescope Innovations (TELI) investor relations material

Innovation and technology focus

• Developing physical AI and self-driving laboratories for high-value specialty chemistry, enabling autonomous process optimization and rapid chemical process development.

• Automation tools use design of experiments and robotic systems to conduct, monitor, and optimize chemical reactions, providing real-time data to AI models.

• Self-driving labs offer 24/7 operation, significant energy efficiency, and reduce R&D costs and time to market for pharmaceuticals.

• Technology enables pharma companies to repatriate R&D, improve data collection for regulatory approval, and pursue smaller or personalized drug markets.

• Automation is being adopted across pharma, chemical, and clean tech industries, with major investments in lab automation.

Commercialization and partnerships

• Products are developed in collaboration with top pharma companies and distributed globally through a partnership with METTLER TOLEDO, reaching 35 countries.

• The first product, funded by a consortium of leading pharma firms, is now used by 15 of the top 20 companies, generating recurring revenue and high gross margins.

• Self-driving lab modules are being deployed by major clients like Pfizer and top European pharma firms, with product prices ranging from CAD 500,000 to CAD 2 million.

• The company leverages its scientific team, including Nobel laureates, to drive innovation and credibility.

Financial performance and outlook

• Achieved 80% year-over-year revenue growth through three quarters, with a trailing 12-month growth rate of 110%.

• Projected to finish the year with CAD 9–9.4 million in revenue, with a market cap of about $50 million USD.

• Raised CAD 6.5 million in October last year, with no immediate need for further fundraising due to ongoing income and grants.

• Revenue streams include contract research, product sales, and future licensing, with clean energy applications providing additional upside.